Clinical Trial Update: Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects [Phase 2, Phase 3]

View source ↗

Summary

This document summarizes the results of a Phase 2/3 clinical trial evaluating maraviroc (UK-427,857) in combination with optimized background therapy versus opt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Selzentry (Maraviroc)

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2012-05-16